Aurinia reports positive long-term safety data from AURORA 2 study of LUPKYNIS in lupus nephritis

Aurinia Pharmaceuticals Inc.

116 voclosporin-treated patients showed stable mean eGFR over 36 months; +2.7 mL/min increase from baseline vs control.
Serious adverse event rates lower in voclosporin group (19% vs 24% control); no deaths vs 4 in control.
Mean UPCR lower in voclosporin group at all time points over three years.
Withdrawal rate lower in voclosporin group (12.9% vs 15.0% control); drug well tolerated overall.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.